Immunoglobulins in chronic inflammatory demyelinating polyneuropathy

Research output: Contribution to journalArticlepeer-review


This article reviews the efficacy and tolerability of intravenous immunoglobulins (IVIg) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including those forms associated with monoclonal gammopathy (paraproteinemic demyelinating neuropathy, PDN). Class I trials demonstrated that IVIg are effective in CIDP. About two-thirds of patients respond to initial treatment; however, most of them require repeated drug doses to maintain improvement. For PDN there are some evidences that IVIg are efficacious; however, it seems that less than 50% of the patients respond to this treatment and the persistence of the response over time has not been thoroughly investigated. The safety profile of immunoglobulins is generally good; however, the possibility of the occurrence of serious adverse effects should always be considered before starting treatment.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 4
Publication statusPublished - Oct 2003


  • Chronic inflammatory demyelinating polyneuropathy
  • Immunoglobulin
  • Monoclonal gammopathy
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Immunoglobulins in chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this